ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,416.45
-0.09%
Dow Jones
39,872.99
0.17%
Gold vs US Dollar
2,421.775
-0.19%
Brent Oil
82.445
-1.30%
Bitcoin
70,256.40
-1.67%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) News

Fate Therapeutics (FATE)

Fate Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FATE
DateTimeSourceHeadlineSymbolCompany
09/05/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202421:01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202413:30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202413:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
03/05/202421:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
22/04/202421:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
03/04/202413:00GlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
02/04/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
19/03/202412:44GlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
05/03/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
05/03/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
04/03/202418:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
01/03/202413:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
26/02/202421:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
26/02/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
26/02/202421:01GlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
15/02/202413:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
12/02/202423:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
02/02/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
02/02/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
02/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
02/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
02/02/202421:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
30/01/202421:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
29/01/202418:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
25/01/202421:19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
10/01/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
10/01/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
10/01/202421:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Your Recent History

LSE
BP.
Bp
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
VAL
Valirx
LSE
YU.
Yu
LSE
POLX
Polarean Imaging
LSE
GKP
Gulf Keystone Petroleum
LSE
SOLG
Solgold
LSE
PHE
Powerhouse Energy
LSE
SYME
Supply@me Capital
LSE
THG
Thg
LSE
MIN
Minoan
LSE
TEK
Tekcapital
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved